Refine by
Cancer Early Detection Articles & Analysis
133 news found
The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies. ...
ByTempus
Cytokine, a subdivision of Creative Proteomics, specializes in providing cytokine research and analytical services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Recently, the product manager of the company was pleased to announce the launch of its Cancer Cytokines Assay, assisting in the detection of multiple cytokine ...
“We are focused on building out our portfolio of assays for early cancer detection and treatment management while maintaining our commitment to continual improvement of our products,” stated Rashid Bux, CEO of BioMark. ...
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
(“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for early cancer ...
It is a special time to gather with loved ones and check-in to make sure everyone is happy and healthy. November is also lung cancer awareness month. VisionGate wants to help you, your family and loved ones learn more about who is at risk, the impact, and the types of lung cancer. Because keeping yourself informed about the risks and early ...
(USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating ...
Its pipeline of products includes two mono-cancer tests designed for early detection of Prostate Cancer and Acute Myeloid Leukemia, and an early detection multi-cancer test to identify any of multiple cancers in a subject from a simple blood draw. “Our ...
Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET -AML test for early ...
Across the US, Transpara is providing hundreds of radiologists with a 'second pair' of eyes helping detect cancers earlier and reduce recall rates. Among the radiologists using this revolutionary AI breast care system, is Dr Englander, Chairman, Pennsylvania Hospital, Department of Radiology. ...
” INOVIQ has multiple patents and patent applications covering its exosome capture and biomarker technologies and products, and was recently granted new patents in the US and Australia for its SubB2M technology. Detecting early-stage cancers Cancers are often diagnosed at late-stage after symptoms have appeared, ...
Nodexus was selected for an SBIR grant for the development of a novel cancer stem cell detection and isolation platform leveraging the core Nodexus technology ...
Rocío Arroyo, researcher, and CEO of Amadix, leads the team that has created an innovative blood-based test that can detect if a healthy person will develop a malignant colon tumour in the future. As an entrepreneur, Rocío turned her scientific knowledge into a viable business model securing private investors in Castile and Leon to found Amadix. Amadix is today a small ...
ByAmadix
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate ...
Kheiron Medical Technologies today announced the appointment of Dr. Wendy DeMartini, Dr. Elizabeth Morris, and Dr. Amy Patel to its US Breast Medical Advisory Board. These appointments reinforce Kheiron’s focus on bringing its artificial intelligence solutions to the US market to help radiologists detect breast cancer earlier. Kheiron is committed to assembling an inclusive advisory board ...
"We are excited to announce the accomplishment of this important milestone in our path to demonstrate the potential of C-Scan to detect colorectal polyps before they may turn into cancer in the average-risk population," said Alex Ovadia, chief executive officer of Check-Cap. ...
The study concluded that "Artificial intelligence (AI)–based screening could detect normal, moderate-risk, and suspicious mammograms in a breast cancer screening programme, which may reduce the radiologist workload. ...
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Arizona Urology, a comprehensive urological care center with three physician offices in the surrounding Phoenix area. Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, ...
(OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point ...
The Cancer Registry of Norway is one of the oldest and most respected organisations of its kind in the world. It collects data and produces statistics of the cancer prevalence in Norway, has the administrative responsibility for the public screening programme in Norway and has an extensive research activity. In a recent study, the Registry used over 120,000 screening examinations from a ...